Fortress Biotech (FBIO) versus MediWound (MDWD) Critical Comparison


Fortress Biotech and MediWound are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation. Fortress Biotech presently has a consensus target price of $10.60, indicating a potential upside of 136.61%.



from Biotech News